Shopping Cart
- Remove All
Your shopping cart is currently empty
TAK-615
Catalog No. T9699Cas No. 1664335-55-0
TAK-615 is commonly used to study pulmonary fibrosis and is a negative allosteric modulator of LPA1 receptors.
TAK-615
Catalog No. T9699Cas No. 1664335-55-0
TAK-615 is commonly used to study pulmonary fibrosis and is a negative allosteric modulator of LPA1 receptors.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $69 | In Stock | |
| 5 mg | $172 | In Stock | |
| 10 mg | $273 | In Stock | |
| 25 mg | $451 | In Stock | |
| 50 mg | $636 | In Stock | |
| 100 mg | $858 | In Stock | |
| 500 mg | $1,710 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $190 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "TAK-615"
Ki16198
T6347355025-13-7
Ki16198 is an orally available LPA receptor antagonist and is a methyl ester derivative of Ki16425. It inhibits LPA1- and LPA3-induced inositol phosphates with Ki values of 0.34 and 0.93 μM, respectively, and can be used in studies of pancreatic carcinogenesis and metastasis.
- $48
Size
QTY
Tetradecyl Phosphonate
T76894671-75-4
Tetradecyl phosphonate is a pan-antagonist of lysophosphatidic acid 1 (LPA1), LPA2, and LPA3 receptors.
- $50
Size
QTY
Radioprotectin-1
5-chloro-2-[4-(1,3-dioxobenzo[de]isoquinolin-2-yl)butylsulfamoyl]benzoic acid
T126841622006-09-0In house
Radioprotectin-1 is a selective agonist of LPA2 with EC50 of 25 nM for murine LPA2 GPCR and exerts radioprotective and radiomitigative action.
- $74
Size
QTY
UCM-05194
UCM05194, UCM 05194
T696472411412-36-5In house
UCM-05194 is a selective LPA1 receptor agonist that can improve neuropathic pain and can be used in the study of progressive system diseases.
- $333
Size
QTY
LPA1 receptor antagonist 1
LPA1 R antagonist 1
T157851396006-71-5In house
LPA1 receptor antagonist 1(LPA1 R antagonist 1) is a selective and potent lysophosphatidic acid (LPA1) receptor antagonist (IC50 : 25 nM) for the study of idiopathic pulmonary fibrosis.
- $147
Size
QTY
H2L5186303
ZINC33388081
T22835139262-76-3
H2L5186303 is an LPA2 antagonist and can be used in studies about asthma treatment.
- $30
Size
QTY
Ki16425
Debio 0719
T6108355025-24-0
Ki16425 (Debio 0719) is a competitive, potent, and reversible antagonist to LPA1, LPA2, and LPA3, with Ki values of 0.34 μM, 6.5 μM, and 0.93 μM, respectively.
- $35
Size
QTY
DBIBB
T220701569309-92-7In house
DBIBB is a non-lipid agonist of specific lysophosphatidic acid (LPA2) type 2 G-protein-coupled receptor. It is a potentially active molecule for the treatment of acute radiation syndrome caused by high intensity gamma rays on hematopoietic and gastrointestinal systems. It is an intermediate in organic synthesis and drug research. DBIBB can be used to prepare various compounds that reduce gastrointestinal radiation syndrome, increase intestinal crypt survival and intestinal cell proliferation, and reduce cell apoptosis.
- $35
Size
QTY
AM966
T42781228690-19-4
AM966, a excellent affinity, specific, oral LPA1(IC50=17 nM) antagonist, suppresses LPA-stimulated intracellular calcium release.
- $33
Size
QTY
LPA2 antagonist 2
T1187536840-10-5
LPA2 antagonist 2 is a selective and potent LPA2 antagonist (IC50: 28.3 nM) with potential anticancer activity, inhibits LPA3, and can be used in the study of cancer.
- $97
Size
QTY
GRI977143
GRI 977143
T22812325850-81-5
GRI977143 is a selective and non-lipid agonist of LPA2 (EC50 = 3.3 μM). GRI977143 inhibits the activation of caspases 3, 7, 8, and 9 and and reduces DNA fragmentation.
- $33
Size
QTY
H2L 5765834
T22834420841-84-5
H2L 5765834 is a lysophosphatidic acid receptors antagonist
- $56
Size
QTY
Select Batch
Purity:99.36%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | TAK-615 is commonly used to study pulmonary fibrosis and is a negative allosteric modulator of LPA1 receptors. |
| In vitro | TAK-615 specifically binds to membranes expressing the human LPA1 receptor with high affinity (Kd = 1.7 ± 0.5 nM) and low affinity (Kd = 14.5 ± 12.1 nM). TAK-615 partially inhibits the LPA response (~40% at 10 μM, IC50 = 23 ± 13 nM in β-arrestin assay; 60% at 10 μM, IC50 = 91 ± 30 nM in calcium mobilization assay). [1] |
| Molecular Weight | 419.44 |
| Formula | C25H22FNO4 |
| Cas No. | 1664335-55-0 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 120 mg/mL (286.10 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy TAK-615 | purchase TAK-615 | TAK-615 cost | order TAK-615 | TAK-615 chemical structure | TAK-615 in vitro | TAK-615 formula | TAK-615 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.